WG
GNCA

Winton Group’s Genocea Biosciences, Inc. GNCA Stock Holding History

Winton Group’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,951
Closed -$27K – 1621
2020
Q3 		$27K Sell
11,951
-16,704
-58% -$43.8K ﹤0.01% 1447
2020
Q2 		$66K Buy
28,655
+11,117
+63% +$25.6K ﹤0.01% 1413
2020
Q1 		$30K Buy
+17,538
New +$35.4K ﹤0.01% 1365

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Winton Group's GNCA Position: Q4 2020 in Review

Winton Group sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2020, closing a stake of 11,951 shares — an estimated $27K sold.

Winton Group first reported a position in GNCA in Q1 2020 and held it in 3 quarters. The position peaked at $66K in Q2 2020. 39 funds tracked by Wall St. Rank hold GNCA as of Q4 2020.

  • Winton Group reported no remaining Genocea Biosciences, Inc. position as of Q4 2020 after selling out during the quarter.
  • Winton Group sold 11,951 Genocea Biosciences, Inc. shares in Q4 2020, an estimated $27K.
  • Winton Group first reported a position in Genocea Biosciences, Inc. in Q1 2020 and held it in 3 quarters.
  • Winton Group's Genocea Biosciences, Inc. position peaked at $66K in Q2 2020.
  • 39 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.